Avidity Biosciences Inc (NASDAQ: RNA) kicked off on Monday, down -5.00% from the previous trading day, before settling in for the closing price of $31.37. Over the past 52 weeks, RNA has traded in a range of $21.51-$56.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 36.27%. While this was happening, its average annual earnings per share was recorded -37.10%. With a float of $109.84 million, this company’s outstanding shares have now reached $120.51 million.
Let’s determine the extent of company efficiency that accounts for 391 employees. In terms of profitability, gross margin is 92.3%, operating margin of -4853.44%, and the pretax margin is -4136.0%.
Avidity Biosciences Inc (RNA) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Avidity Biosciences Inc is 8.87%, while institutional ownership is 107.71%. The most recent insider transaction that took place on Jun 11 ’25, was worth 657,694. In this transaction Chief Scientific Officer of this company sold 20,000 shares at a rate of $32.88, taking the stock ownership to the 80,195 shares. Before that another transaction happened on Jun 11 ’25, when Company’s Officer proposed sale 20,000 for $33.62, making the entire transaction worth $672,400.
Avidity Biosciences Inc (RNA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -37.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.77% during the next five years compared to -34.37% drop over the previous five years of trading.
Avidity Biosciences Inc (NASDAQ: RNA) Trading Performance Indicators
Take a look at Avidity Biosciences Inc’s (RNA) current performance indicators. Last quarter, stock had a quick ratio of 16.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 402.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.01, a number that is poised to hit -0.95 in the next quarter and is forecasted to reach -4.45 in one year’s time.
Technical Analysis of Avidity Biosciences Inc (RNA)
Looking closely at Avidity Biosciences Inc (NASDAQ: RNA), its last 5-days average volume was 1.6 million, which is a jump from its year-to-date volume of 1.47 million. As of the previous 9 days, the stock’s Stochastic %D was 8.05%. Additionally, its Average True Range was 2.09.
During the past 100 days, Avidity Biosciences Inc’s (RNA) raw stochastic average was set at 50.27%, which indicates a significant increase from 0.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.32% in the past 14 days, which was lower than the 73.40% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $29.98, while its 200-day Moving Average is $35.54. However, in the short run, Avidity Biosciences Inc’s stock first resistance to watch stands at $31.05. Second resistance stands at $32.29. The third major resistance level sits at $32.93. If the price goes on to break the first support level at $29.16, it is likely to go to the next support level at $28.52. Should the price break the second support level, the third support level stands at $27.27.
Avidity Biosciences Inc (NASDAQ: RNA) Key Stats
The company with the Market Capitalisation of 3.59 billion has total of 120,520K Shares Outstanding. Its annual sales at the moment are 10,900 K in contrast with the sum of -322,300 K annual income. Company’s last quarter sales were recorded 1,570 K and last quarter income was -115,770 K.
